title: Qianliening capsule treats benign prostatic hyperplasia via induction             of prostatic cell apoptosis.
abstract: The aim of this study was to evaluate the therapeutic efficacy of Qianliening             capsule (QC) against benign prostatic hyperplasia (BPH) in vivo in a BPH rat model,             as well as to investigate the effects of QC on prostatic cell apoptosis and the             possible molecular mechanisms mediating its anti-BPH activity. Fifty male Sprague‑Dawley             (SD) rats were randomly classified into five groups. The rats of the four groups             were castrated and subcutaneously injected with testosterone propionate to generate             BPH. One week after model establishment, BPH rats were orally administrated with             various doses of QC daily for 28 days. The prostatic tissues from BPH rats were             collected to evaluate prostatic index (PI). The histological changes of prostate             were observed by hematoxylin and eosin staining. TUNEL analysis was performed             to examine cell apoptosis. The mRNA expression of Bcl-2 and Bax in prostatic tissues             was determined by reverse transcription‑polymerase chain reaction (RT-PCR). The             protein expression of Bcl-2, Bax and cleaved caspase 3 were examined by immunohistochemistry.             Administration with QC significantly decreased PI in a dose-dependent manner (P<0.05             or P<0.01) and improved prostatic hyperplasia in BPH rats. Additionally, QC             treatment induced prostatic cell apoptosis in a dose-dependent manner. Moreover,             QC promoted the cleavage of caspase 3, an indicator of apoptosis, in a dose-dependent             manner. Furthermore, following QC treatment, the expression ratio of pro‑apoptotic             Bax to anti‑apoptotic Bcl-2 in prostatic tissues was increased in a dose-dependent             manner. As a result, QC was effective in the treatment of BPH in rats. Promoting             apoptosis of prostatic cells may therefore be one of the mechanisms by which QC             treats BPH.
authors: Department of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Minhou Shangjie, Fuzhou, Fujian 350122, PR China.
authors: Haiyin
authors: H
authors: Zheng
authors: Wei
authors: W
authors: Xu
authors: Jiumao
authors: J
authors: Lin
authors: Jun
authors: J
authors: Peng
authors: Zhenfeng
authors: Z
authors: Hong
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3 / Q000378:metabolism; D004195:Disease Models, Animal; D004365:Drugs, Chinese Herbal / Q000494:pharmacology* / Q000627:therapeutic use; D007150:Immunohistochemistry; D008297:Male; D011470:Prostatic Hyperplasia / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012720:Severity of Illness Index; D043343:Testosterone Propionate / Q000633:toxicity; D051028:bcl-2-Associated X Protein / Q000235:genetics / Q000378:metabolism
chemical_list: D004365:Drugs, Chinese Herbal; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein; C579120:qianliening; D053148:Caspase 3; D043343:Testosterone Propionate